Endeavor notches major mid-stage trial win, says IPF drug can reverse disease

Endeavor BioMedicines said taladegib met the primary endpoint in a Phase 2b study, claiming it had the potential to reverse the course of IPF in a setting where current therapies only slow disease down. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech:…

Source: Endpoints News